Part 1 Part 2 Part 3

References

1. Queiroz ML, Dantas DC: B lymphocytes in mercury-exposed workers, Pharmacology & Toxicology 1997 Sept;81(3):130-3.

2. Bridoux F, et al: Transforming growth factor beta (TGF-beta)-dependent inhibition of T-helper cell 2 (Th-2)-induced autoimmunity by major histocompatibility complex (MHC) class II-specific regulatory CD4(+) T-cell lines, Journal of Experimental Medicine 1997 May 19;185(10):1769-75.

3. Cavalleri A, Gobba F: Reversible color vision loss in occupational exposure to metallic mercury, Environmental Research 1998 May;77(2):173-7.

4. Korogi Y, et al: Representation of the visual field in the striate cortex: comparison of MR findings with visual field deficits in organic mercury poisoning (Minamata disease), American Journal of Neuroradiology 1997 Jun-Jul;18(6):1127-30.

5. Eto K: Pathology of Minamata disease, Toxicologic Pathology 1997 Nav-Dec;25(6):614-23.

6. Maiorino RM, et al: Determination and metabolism of dithiol chelating agents XV, Journal of Pharmacology & Experimental Therapeutics 1993 Dec;267(3):1221-6.

7. Gurer H, et al: Antioxidant effects of N-acetylcyteine and Succimer in red blood cells from lead-exposed rats, Toxicology, 1998 Jul 17; 128(3):181-9.

8. Zhang J: Clinical observations in ethyl mercury chloride poisoning, American Journal of Industrial Medicine, 1984; 5(3):251-8.

9. Keith RL: Utilization of renal slices to evaluate the efficacy of chelating agents for removing mercury from the kidney, Toxicology, 1997 Jan 15; 116(1-3):67-75.

10. Ding GS, Liang YY: Antidotal effects of dimercaptosuccinic acid, Journal of Applied Toxicology, 1991 Feb;11(1):7-14.

11. Zabinski Z: The activity of erythrocyte enzymes and basic indices of peripheral blood erythrocytes from workers chronically exposed to mercury vapors, Toxicology & Industrial Health 2000 Feb;16(2):58-64.

12. Gerr F, Frumkin H, Hodgins P: Hemolytic anemia following succimer administration in a glucose-6-phosphate dehydrogenase deficient patient, Journal of Toxicology -- Clinical Toxicology 1994;32(5):569-75.

13. Zabinski Z: The activity of erythrocyte enzymes and basic indices of peripheral blood erythrocytes from workers chronically exposed to mercury vapors, Toxicology & Industrial Health 2000 Feb;16(2):58-64.

14. Woods JS, Fowler BA: Renal porphyrinuria during chronic methyl mercury exposure, Journal of Laboratory & Clinical Medicine 1977 Aug;90(2):266-72.

15. Woods JS: Altered porphyrin metabolism as a biomarker of mercury exposure and toxicity, Canadian Journal of Physiology & Pharmacology 1996 Feb;74(2):210-215.

16. Vinay SP, Raghn KG, Sood PP: Dose and duration related methylmercury deposition, glycosidase inhibition, myelin degeneration and chelation therapy, Cellular and Molecular Biology, 1990; 36(5):609-23.

17. Gong Z, Evans HL: Effect of chelation with meso-dimercaptosuccinic acid (DMSA) before and after the appearance of lead-induced neurotoxicity in the rat, Toxicology & Applied Pharmacology, 1997 Jan; 144(2):205-14.

18. Jorgensen FM: Succimer: the first approved oral lead chelator, American Family Physician 1993 Dec;48(8):1495-1502.

19. Aposhian HV, et al: Urinary excretion of meso-2,3-dimercaptosuccinic acid in human subjects, Clinical Pharmacology & Therapeutics 1989 May;45(5):520-6.

20. Chisolm JJ Jr: Safety and efficacy of meso-2,3-dimercaptosuccinic acid (DMSA) in children with elevated blood lead concentrations, Journal of Toxicology -- Clinical Toxicology 2000;38(4):365-75.

21. Butterworth RF, Gonce M, Barbeau A: Accumulation and removal of Hg203 in different regions of the rat brain, Canadian Journal of Neurological Sciences 1978 Nov; 5(4):397-400.

22. Kostyniak PJ: Methylmercury removal in the dog during infusion of 2,3 dimercaptosuccinic acid (DMSA, Journal of Toxicology and Environmental Health, 1983 Apr-Jun; 11(4-6):947-57.

23. Farris FF, et al: Physiological model for the pharmacokinetics of methyl mercury in the growing rat, Toxicology & Applied Pharmacology, 1993 Mar; 119(1):74-90.

24. Opitz H, et al: Demonstration of mercury in the human brain and other organs 17 years after metallic mercury exposure, Clinical Neuropathology, 1996 May-Jun; 15(3):139-44.

25. Magos L: Neurotoxicity, anorexia and the preferential choice of antidote in methylmercury intoxicated rats, Neurobehavioral Toxicology and Teratology, 1982 Nov-Dec; 4(6):643-6.

26. Aposhian HV, et al: Anti-Lewisite activity and stability of meso-dimercaptosuccinic acid and 2,3 dimercapto-1-propanesulfonic acid, Life Sciences 1982 Nov 8; 31(19):2149-56.

27. Mann KV, Travers JD: Succimer, an oral lead chelator, Clinical Pharmacology, 1991 Dec; 10(12):914-22.

28. Jorgensen FM: Succimer: the first approved oral lead chelator, American Family Physician, 1993 Dec; 48(8):1495-1502.

29. Fang X, Fernando Q: A comparative study of meso- and rac-2,3 dimercaptosuccinic acids and their zinc complexes in aqueous solution, Chemical Research in Toxicology, 1994 Nov-Dec; 7(6):770-8.

30. Flora SJ, Tandon SK: Beneficial effects of zinc supplementation during chelation treatment of lead intoxication in rats, Toxicology, 1990 Nov; 64(2):129-39.

31. Ziegler C, et al: Alpha-lipoic acid in the treatment of diabetic neuropathy in Germany: current evidence from clinical trials, Experimental & Clinical Endocrinology & Diabetes 1999;107(7):421-30.

32. Ziegler C, et al: Alpha-lipoic acid in the treatment of diabetic neuropathy in Germany: current evidence from clinical trials, Experimental & Clinical Endocrinology & Diabetes 1999;107(7):421-30.

33. Gregus Z, et al: Effect of lipoic acid on biliary excretion of glutathione and metals, Toxicology & Applied Pharmacology 1992 May;114(1):88-96.

34. Smith DR, et al: Succimer and the urinary excretion of essential elements in a primate model of childhood lead exposure, Toxicological Sciences 2000 Apr;54(2):473-80.

35. Ding GS, Liang YY: Antidotal effects of dimercaptosuccinic acid, Journal of Applied Toxicology, 1991 Feb; 11(1):7-14.

36. Tan DX, et al: Significance of melatonin in antioxidative defense systems: reaction and products, Biological Signals & Receptors 2000 May-Aug;9(3-4):137-59.

37. Olivieri G, et al: Mercury induces cell cytotoxicity and oxidative stress and increases beta-amyloid secretion and tau phosphorylation in SHSY5Y neuroblastoma cells, Journal of Neurochemistry 2000 Jan;74(1):231-6.

38. Martin M, et al: Melatonin-induced increased activity of the respiratory chain complexes I and IV can prevent mitochondrial damage induced by ruthenium red in vivo, Journal of Pineal Research, 2000 May; 28(4):242-8.

39. Gordon N: The therapeutics of melatonin: a pediatric perspective, Brain & Development 2000 Jun;22(4):213-7.

40. Witschi A, et al: The systemic availability of oral glutathione, European Journal of Clinical Pharmacology 1992;43(6):667-9.

41. Yim CY, et al: Use of N-acetylcysteine to increase intracellular glutathione during induction of antitumor responses by IL-2, Journal of Immunology, 1994 Jan 15; 152(12):5796-805.

42. Meyer A, Buhl R, Magnussen H: The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis, European Respiratory Journal, 1994 Mar; 7(3):431-6.

43. McCourtie J, Douglas LJ: Relationship between cell surface composition of Candida albicans and adherence to acrylic after growth on different carbon sources, Infection & Immunity 1981 Jun; 32(3):1234-41.

44. Burke V, Gracey M: An experimental model of gastrointestinal candidiasis, Journal of Medical Microbiology, 1980 Feb; 13(1):103-10.

45. Jeske J, et al: Evaluation of therapeutic efficacy of ketoconazole and itraconazole in the treatment of alimentary tract candidiasis, Medical Science Monitor, 1999 5(1):141-145.

46. Metzger S, Hoffman H: Fluconazole-resistant Candida specimens from HIV-infected patients with recurrent Candida stomatitis: Crossresistance to itraconazole and ketoconazole, Mycoses, 1997 Supp. 40(1):56-63.

47. Velentin A, et al: Comparative resistance of Candida albicans clinical isolates to fluconazole and itraconazole in vitro and in vivo in a murine model, Antimicrobial Agents & Chemotherapy, 1996 40(6):1342-1345.

Return to Table of Contents #225